n-methyl-3,4-methylenedioxyamphetamine has been researched along with Parkinson Disease, Secondary in 13 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beaudoin-Gobert, M | 1 |
| Météreau, E | 1 |
| Duperrier, S | 1 |
| Thobois, S | 1 |
| Tremblay, L | 1 |
| Sgambato, V | 1 |
| Lappin, JM | 1 |
| Sara, GE | 1 |
| Schmidt, WJ | 1 |
| Mayerhofer, A | 1 |
| Meyer, A | 1 |
| Kovar, KA | 1 |
| Parrott, AC | 2 |
| Buchanan, T | 2 |
| Heffernan, TM | 1 |
| Scholey, A | 1 |
| Ling, J | 2 |
| Rodgers, J | 2 |
| Kuniyoshi, SM | 1 |
| Jankovic, J | 1 |
| Sumnall, HR | 1 |
| Jerome, L | 2 |
| Doblin, R | 2 |
| Mithoefer, MC | 1 |
| Scholey, AB | 1 |
| Heffernan, T | 1 |
| Kish, SJ | 1 |
| Mithoefer, M | 1 |
| Mintzer, S | 1 |
| Hickenbottom, S | 1 |
| Gilman, S | 1 |
| Borg, GJ | 1 |
| Sewell, RA | 1 |
| Cozzi, NV | 1 |
| Baggott, M | 1 |
| Mendelson, J | 1 |
| Jones, R | 1 |
2 reviews available for n-methyl-3,4-methylenedioxyamphetamine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Psychostimulant use and the brain.
Topics: Amphetamine; Amphetamine-Related Disorders; Brain; Central Nervous System Stimulants; Cocaine; Cocai | 2019 |
What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
Topics: Brain; Carrier Proteins; Hallucinogens; Humans; Membrane Glycoproteins; Membrane Transport Proteins; | 2003 |
11 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates.
Topics: Animals; Brain; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug- | 2018 |
Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Animals; Catalepsy; Dopamine Antagonist | 2002 |
Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.
Topics: Brain; Dopamine; Hallucinogens; Humans; Illicit Drugs; N-Methyl-3,4-methylenedioxyamphetamine; Parki | 2003 |
MDMA and Parkinsonism.
Topics: Adult; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease, Secondary | 2003 |
Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.
Topics: Animals; Dopamine; Hallucinogens; Humans; Illicit Drugs; N-Methyl-3,4-methylenedioxyamphetamine; Neu | 2004 |
The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).
Topics: Animals; Clinical Trials as Topic; Dopamine; Hallucinogens; Humans; Illicit Drugs; N-Methyl-3,4-meth | 2004 |
Ecstasy use-Parkinson's disease link tenuous.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Dose-Response Relationship, Drug; Hallucinogens; | 2004 |
Parkinsonism after taking ecstasy.
Topics: Adult; Hallucinogens; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease, Secon | 1999 |
More about parkinsonism after taking ecstasy.
Topics: Adult; Deception; Ethics, Medical; Hallucinogens; Humans; Male; Marijuana Abuse; N-Methyl-3,4-methyl | 1999 |
More about parkinsonism after taking ecstasy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Basal Ganglia; Dopamine Agents; Hallucinogens; Humans; | 1999 |
More about parkinsonism after taking ecstasy.
Topics: Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease, Secondary; Time Fa | 1999 |